Previous 10 | Next 10 |
2023-05-19 06:50:34 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips AI penny stocks offer investors a thrilling opportunity to tap into the fast-evolving artificial intelligence space. AI penny stocks have limited financial resources and modest profits, but...
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announ...
2023-05-13 15:52:08 ET Lantern Pharma Inc. (LTRN) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Nicole Leber - Investor Relations Associate Panna Sharma - Chief Executive Officer and President David Margrave - Chief Financial Office...
2023-05-09 16:16:21 ET Lantern Pharma press release ( NASDAQ: LTRN ): Q1 GAAP EPS of -$0.36 beats by $0.12 . For further details see: Lantern Pharma GAAP EPS of -$0.36 beats by $0.12
Dosed first patient in the Phase 2 Harmonic™ clinical trial; a study for the unique population of non-small lung cancer patients who are never-smokers and who make up 15-20% of all lung cancer cases. Submission of the IND application for LP-184 to the US Food and Drug Administration (F...
Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial Canada NewsWire BELTSVILLE, Md. , May 3, 2023 /CNW/ -- Reprocell USA , a CRO, has been awarded a contract to provide support for Lantern Pharma's Phase 2 c...
Webcast to be held Tuesday, May 9, 4:30 p.m. ET, register here , or at the link below. Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence (AI) and machine learning (ML) platform to transform th...
The Blood-Brain-Barrier (BBB) prevents 98% of drugs from entering the brain and is a major limiting factor in the development of brain and central nervous system (CNS) drugs. Lantern’s AI algorithms for predicting BBB permeability have 89-92% accuracy, have been optimized to rapidly ge...
2023-04-13 12:04:53 ET Lantern Pharma ( NASDAQ: LTRN ) said the U.S. Patent and Trademark Office (USPTO) issued a notice of allowance for an application related to its blood cancer drug candidate LP-284 ((+)N-hydroxy-N-(methylacylfulvene)urea). The U.S. patent application...
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announ...
News, Short Squeeze, Breakout and More Instantly...
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagn...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...